SARS-CoV-2 Virus ELISA kit (Nucleocapsid Protein)

berthold_logo.jpg

​※ Move to the official distributor page

Manual

Flyer

・Made in Japan

・Minimally invasive sample volume as of only 10 μL

・Apply the blood directly

・All necessary reagents are included in the kit.

・Measurement time is only 15 minutes.

・Made in Japan

・Minimally invasive sample volume as of only 10 μL

・Apply the blood directly

・All necessary reagents are included in the kit.

・Measurement time is only 15 minutes.

Features

・Made in Japan

・Minimally invasive sample volume as of only 10 μL

・Apply the blood directly

・All necessary reagents are included in the kit.

・Measurement time is only 15 minutes.

​製品の主な仕様

測定方法:   免疫クロマトグラフ法

測定試料:   鼻腔ぬぐい液、鼻咽頭ぬぐい液

測定時間:   15分 

保管温度:   2-28 ℃

品質保証期限:   本品の有効期限は製造後 12 カ月です。

キット内容

1. テストスティック

        着色ナノ粒子標識抗SARS-CoV-2モノクローナル抗体(ウサギ)

        抗SARS-CoV-2モノクローナル抗体(マウス)

2. 検体処理液

        緩衝剤、界面活性剤、ブロッキング剤、0.05 % アジ化ナトリウム

3. ノズル

×10個

×10個

×10個

Features

測定原理

  1. The immobilized SARS-CoV-2 recombinant spike protein on a plate is reacted with the antibody (hereinafter referred to as anti-spike protein antibody) in a sample that recognizes it.

  2.  After the reaction, the sample is removed by washing.

  3.  React anti-spike protein antibody in the plate with HRP (horseradish peroxidase)- conjugated anti-human  IgM / IgG antibodies.

  4. Remove excess HRP-conjugated anti-human IgM / IgG antibodies by washing. Add a chromogenic substrate and measure the absorbance.

  1. The immobilized SARS-CoV-2 recombinant spike protein on a plate is reacted with the antibody (hereinafter referred to as anti-spike protein antibody) in a sample that recognizes it.

  2.  After the reaction, the sample is removed by washing.

  3.  React anti-spike protein antibody in the plate with HRP (horseradish peroxidase)- conjugated anti-human  IgM / IgG antibodies.

  4. Remove excess HRP-conjugated anti-human IgM / IgG antibodies by washing. Add a chromogenic substrate and measure the absorbance.

  1. The immobilized SARS-CoV-2 recombinant spike protein on a plate is reacted with the antibody (hereinafter referred to as anti-spike protein antibody) in a sample that recognizes it.

  2.  After the reaction, the sample is removed by washing.

  3.  React anti-spike protein antibody in the plate with HRP (horseradish peroxidase)- conjugated anti-human  IgM / IgG antibodies.

  4. Remove excess HRP-conjugated anti-human IgM / IgG antibodies by washing. Add a chromogenic substrate and measure the absorbance.

  1. The immobilized SARS-CoV-2 recombinant spike protein on a plate is reacted with the antibody (hereinafter referred to as anti-spike protein antibody) in a sample that recognizes it.

  2.  After the reaction, the sample is removed by washing.

  3.  React anti-spike protein antibody in the plate with HRP (horseradish peroxidase)- conjugated anti-human  IgM / IgG antibodies.

  4. Remove excess HRP-conjugated anti-human IgM / IgG antibodies by washing. Add a chromogenic substrate and measure the absorbance.

  1. The immobilized SARS-CoV-2 recombinant spike protein on a plate is reacted with the antibody (hereinafter referred to as anti-spike protein antibody) in a sample that recognizes it.

  2.  After the reaction, the sample is removed by washing.

  3.  React anti-spike protein antibody in the plate with HRP (horseradish peroxidase)- conjugated anti-human  IgM / IgG antibodies.

  4. Remove excess HRP-conjugated anti-human IgM / IgG antibodies by washing. Add a chromogenic substrate and measure the absorbance.

測定の意義

新種のコロナウイルス(SARS-CoV-2)による感染症は、2019 年 12 月に中華人民共和国湖北省武漢市で初めて確認されました。COVID-19 の感染は全世界へ拡大し、2020 年 3 月に WHO によるパンデミックの宣言がなされました。SARS-CoV-2 の確認には、主に鼻咽頭ぬぐい液を試料として、RT-PCR 法 により実施されています。核酸検査は、高感度に SARS-CoV-2 遺伝子を検出できますが、その実施には専用の設備と時間試が必要、且つ試料の取り扱いが容易ではありません。一方、抗原検出法は PCR 法ほど感度は高くありませんが、ウイルス抗原タンパク質を標的としているため、核酸試料と比較し て、試料の取扱が容易く、免疫化学的手法により簡便、迅速に検出することができます。PCR 法と抗原検出法とで採取部位や採取タイミングにおける詳細な知見は未だ十分ではありませんが、世界中で抗原検査の応用についての多様な試みがなされています。

参考文献

1.) 病原体検出マニュアル 2019-nCoV- Ver.2.9.1、国立感染症研究所

2.) 新型コロナウイルス(SARS-CoV-2)検査法の運用についてのガイドライン第3版、国立感染症研究所

3.) COVID-19 に関する WHO・中国合同調査報告書、WHO 神戸センター公表和訳

4.) WHOホームページ:“Naming the coronavirus disease (COVID-19) and the virus that causes it”                  (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the- coronavirus-disease-(covid-2019)-and-the-virus-that- causes-it)

5.) 新型コロナウイルス感染症(COVID-19)病原体検査の指針、第1版、令和2年10月2日発、厚生労働省

Copyright ©2018 cellspect All Rights Reserved. Wix.comで作成したホームページです。